Dermata Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Statements of Stockholders and Members Equity (Deficit)

Statements of Stockholders and Members Equity (Deficit) - USD ($)	Total	Class A Common	Class B Common	Series 1 Preferred	Series 1a Preferred	Series 1a Warrants	Series 1b Preferred	Series 1c Preferred	Retained Earnings (Accumulated Deficit)	Series 1d Preferred	Common Stock	Preferred Stock	Additional Paid-In Capital	Preferred Stock Warrants
Balance, shares at Dec. 31, 2019		508,777	1,761,908	6,906,244	5,000,000	1,437,978	6,500,000	44,767,474
Balance, amount at Dec. 31, 2019	$ (210,159)	$ 10,430	$ 2,342,853	$ 6,833,877	$ 4,361,331	$ 723,431	$ 4,119,595	$ 6,241,592	$ (24,843,268)
Class B Common Units issued, shares			2,439
Class B Common Units issued, amount	(1,000,000)
Series 1c Preferred Units issued, shares								1,785,714
Series 1c Preferred Units issued, amount	250,000							$ 250,000
Exercise of Series 1a Preferred Warrant Units, shares					18,750	(18,750)
Exercise of Series 1a Preferred Warrant Units, amount	18,750				$ 18,750
Net loss	(3,236,530)								(3,236,530)
Balance, shares at Dec. 31, 2020		508,777	1,767,477	6,906,244	5,018,750	1,419,228	6,500,000	46,553,188
Balance, amount at Dec. 31, 2020	(3,177,939)	$ 10,430	$ 2,342,853	$ 6,833,877	$ 4,380,081	$ 723,431	$ 4,119,595	$ 6,491,592	(28,079,798)
Net loss	(7,902,477)								(7,902,477)
Series 1d Preferred Units issued, shares										6,065,989
Series 1d Preferred Units issued, amount	5,034,801									$ 5,034,801
Class B Common Units forfeited, shares			(22,494)
Class B Common Units forfeited, amount	0
Conversion of Common Units to Common Stock, shares		(508,777)	(1,744,983)								1,911,009
Conversion of Common Units to Common Stock, amount	0	$ (10,430)	$ (2,342,853)								$ 191
Conversion of Preferred Units to Preferred Stock, shares				(6,906,244)	(5,018,750)		(6,500,000)	(46,553,188)		(6,065,989)		71,044,171
Conversion of Preferred Units to Preferred Stock, amount	0			$ (6,833,877)	$ (4,380,081)		$ (4,119,595)	$ (6,491,592)		$ (5,034,801)		$ 7,104	$ 26,852,842
Conversion of Warrant Units to Preferred Stock, shares						(1,419,228)								1,419,228
Conversion of Warrant Units to Preferred Stock, amount	0					$ (723,431)							723,289	$ 723,431
Redemption of Series 1c preferred shares, shares												(5,221,156)
Redemption of Series 1c preferred shares, amount	(1,000,000)											$ (522)	(999,478)
Conversion of Preferred Stock to Common Stock, shares											3,813,973	(65,823,015)
Conversion of Preferred Stock to Common Stock, amount	0										$ 381	$ (6,582)	6,200
Conversion of Preferred Stock Warrants to Common Stock Warrants, shares														(1,419,228)
Conversion of Preferred Stock Warrants to Common Stock Warrants, amount	0												142	$ (142)
Conversion of Convertible Debt to Common Stock, shares											32,219
Conversion of Convertible Debt to Common Stock, amount	180,434										$ 3		180,430
Issuance of Common Stock and warrants, net issuance costs, shares											2,571,428
Issuance of Common Stock and warrants, net issuance costs, amount	15,385,563										$ 257		15,385,306
Stock-based compensation	1,586,722												1,586,722
Balance, shares at Dec. 31, 2021											8,328,629
Balance, amount at Dec. 31, 2021	$ 10,107,104								$ (35,982,275)		$ 833		$ 46,088,546